DK3628680T3 - Modulering af komplementaktivitet - Google Patents

Modulering af komplementaktivitet Download PDF

Info

Publication number
DK3628680T3
DK3628680T3 DK19194070.9T DK19194070T DK3628680T3 DK 3628680 T3 DK3628680 T3 DK 3628680T3 DK 19194070 T DK19194070 T DK 19194070T DK 3628680 T3 DK3628680 T3 DK 3628680T3
Authority
DK
Denmark
Prior art keywords
modulation
complementary activity
complementary
activity
Prior art date
Application number
DK19194070.9T
Other languages
English (en)
Inventor
Ketki Ashok Dhamnaskar
Daniel Elbaum
Kristopher Josephson
Kelley Cronin Larson
Zhong Ma
Nathan Ezekiel Nims
Kathleen Seyb
Guo-Qing Tang
Douglas A Treco
Zhaolin Wang
Ping Ye
Hong Zheng
Sarah Jacqueline Perlmutter
Alonso Ricardo
Robert Paul Hammer
Michelle Denise Hoarty
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3628680(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3628680T3 publication Critical patent/DK3628680T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19194070.9T 2014-06-12 2015-06-12 Modulering af komplementaktivitet DK3628680T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462011368P 2014-06-12 2014-06-12
US201462077460P 2014-11-10 2014-11-10
US201562108772P 2015-01-28 2015-01-28
EP15807069.8A EP3154561B1 (en) 2014-06-12 2015-06-12 Modulation of complement activity

Publications (1)

Publication Number Publication Date
DK3628680T3 true DK3628680T3 (da) 2021-10-11

Family

ID=54834568

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15807069.8T DK3154561T3 (da) 2014-06-12 2015-06-12 Modulering af komplementaktivitet
DK19194070.9T DK3628680T3 (da) 2014-06-12 2015-06-12 Modulering af komplementaktivitet

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15807069.8T DK3154561T3 (da) 2014-06-12 2015-06-12 Modulering af komplementaktivitet

Country Status (29)

Country Link
US (7) US10106579B2 (da)
EP (4) EP3973994A1 (da)
JP (4) JP6432954B2 (da)
KR (3) KR102346228B1 (da)
CN (2) CN111187338B (da)
AP (1) AP2016009612A0 (da)
AU (3) AU2015274482B2 (da)
BR (3) BR112016029076B1 (da)
CA (3) CA3174909A1 (da)
CY (2) CY1122227T1 (da)
DK (2) DK3154561T3 (da)
ES (2) ES2895029T3 (da)
FI (1) FIC20240015I1 (da)
FR (1) FR24C1022I1 (da)
HR (2) HRP20211561T8 (da)
HU (3) HUE055931T2 (da)
IL (3) IL249093B (da)
LT (2) LT3628680T (da)
MX (2) MX2016016449A (da)
NL (1) NL301275I2 (da)
NZ (1) NZ727420A (da)
PL (2) PL3154561T3 (da)
PT (2) PT3628680T (da)
RS (2) RS59353B1 (da)
RU (1) RU2670988C2 (da)
SG (1) SG11201610222UA (da)
SI (2) SI3154561T1 (da)
WO (1) WO2015191951A2 (da)
ZA (3) ZA201706379B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ727420A (en) 2014-06-12 2018-06-29 Ra Pharmaceuticals Inc Modulation of complement activity
EP3988110A1 (en) * 2015-01-28 2022-04-27 RA Pharmaceuticals, Inc. Modulators of complement activity
RS64067B1 (sr) * 2015-12-16 2023-04-28 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
US11026945B2 (en) 2016-04-29 2021-06-08 The Trustees Of The University Of Pennsylvania Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
MX2019006527A (es) * 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
US11814444B2 (en) 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
EP3810177A4 (en) * 2018-06-21 2022-05-11 RA Pharmaceuticals, Inc. CYCLIC PEPTIDES FOR PCSK9 INHIBITION
CA3115828A1 (en) 2018-10-22 2020-04-30 Ra Pharmaceuticals, Inc. Neurological disease treatment with zilucoplan
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
CN113710230A (zh) * 2019-04-24 2021-11-26 Ra制药公司 用于调节补体活性的组合物和方法
ES2973767T3 (es) 2019-06-04 2024-06-24 Ra Pharmaceuticals Inc Tratamiento de enfermedades inflamatorias con inhibidores del complemento
WO2021050885A1 (en) 2019-09-12 2021-03-18 Ra Pharmaceuticals, Inc. Neurological disease treatment with complement inhibitors
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
AU2022210988B9 (en) 2021-01-20 2023-12-14 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2022177635A2 (en) * 2021-02-22 2022-08-25 Ra Pharmaceuticals, Inc. Compositions and methods for microbial disease treatment
WO2023215294A1 (en) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Complement pathway inhibition for wound healing
WO2024039636A1 (en) * 2022-08-16 2024-02-22 Ps Therapy, Inc. Methods of use for disulfiram and metabolites thereof

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361943B1 (en) 1996-10-17 2002-03-26 Mitsubishi Chemical Corporation Molecule that homologizes genotype and phenotype and utilization thereof
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2641081A1 (da) * 1988-12-23 1990-06-29 Medgenix Group
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69032483T2 (de) 1989-10-05 1998-11-26 Optein, Inc., Seattle, Wash. Zellfreie synthese und isolierung von genen und polypeptiden
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
EP0700522A1 (en) 1993-05-28 1996-03-13 Chiron Corporation Method for selection of biologically active peptide sequences
EP0710243B1 (en) 1993-06-29 2000-06-14 Ferring B.V. Synthesis of cyclic peptides
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
RU2233878C2 (ru) 1997-01-21 2004-08-10 Дзе Дженерал Хоспитал Корпорейшн Способ отбора желательного белка и нуклеиновой кислоты, средства для его осуществления
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
KR100659753B1 (ko) 1998-08-07 2006-12-20 에미스페어 테크놀로지스, 인코포레이티드 활성제 전달용 화합물 및 조성물
EP1115847A1 (en) * 1998-09-25 2001-07-18 Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
US20030232014A1 (en) * 2002-03-01 2003-12-18 Mds Proteomics Inc. Phosphorylated proteins and uses related thereto
US7411039B2 (en) * 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US8007804B2 (en) * 2002-11-15 2011-08-30 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
KR20110059664A (ko) * 2003-05-05 2011-06-02 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
ES2522525T3 (es) 2003-05-15 2014-11-14 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
US7348401B2 (en) 2003-09-10 2008-03-25 Innate Biotech, Inc. Peptides that inhibit complement activation
EP1706098A4 (en) 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060027059A1 (en) 2004-08-09 2006-02-09 Chih-Ching Hsien Extendable handle device
US20090054623A1 (en) * 2004-12-17 2009-02-26 Neose Technologies, Inc. Lipo-Conjugation of Peptides
CA2595902C (en) 2005-01-24 2017-08-22 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
JP5198261B2 (ja) 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
AU2006311803C1 (en) 2005-11-04 2015-05-14 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
EP3167888B1 (en) 2006-03-15 2024-05-01 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP1876183A1 (en) * 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
PL2698166T3 (pl) 2006-10-10 2016-03-31 Regenesance B V Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
WO2008109742A1 (en) 2007-03-06 2008-09-12 Novo Nordisk A/S Modulation of complement system activation for treatment of bleeding-related inflammation
WO2008113834A2 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
KR20100014486A (ko) 2007-04-30 2010-02-10 알콘 리서치, 리미티드 보체 인자 ｄ의 저해제를 사용한 연령 관련 황반변성의 치료
SG10201608952QA (en) 2007-06-07 2016-12-29 Genentech Inc C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
MX2010003630A (es) 2007-10-02 2010-04-21 Potentia Pharmaceuticals Inc Administracion sostenida de analogos de compstatina desde geles.
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010014830A2 (en) 2008-07-30 2010-02-04 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
MY159396A (en) * 2008-08-05 2016-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
AU2009290137A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
NZ592786A (en) 2008-11-10 2013-02-22 Alexion Pharma Inc Methods and compositions for treating complement-associated disorders using eculizumab
AU2009230735B1 (en) 2009-01-08 2010-01-21 Shane Ramodien Electronic equipment housing
EP2488203B1 (en) 2009-10-16 2016-12-07 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
EA201290286A1 (ru) 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
DK2513140T3 (da) 2009-12-16 2016-01-18 Novo Nordisk As Dobbeltacylerede GLP-1-derivater
US9172511B2 (en) 2009-12-24 2015-10-27 Samsung Electronics Co., Ltd. Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
ES2659409T3 (es) * 2010-03-12 2018-03-15 The Regents Of The University Of California Conjugados de lípido-péptido-polímero y nanopartículas de los mismos
WO2011139343A2 (en) * 2010-04-28 2011-11-10 Wu Nian Amino acid linked peg-lipid conjugates
US20110269807A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
KR20140145947A (ko) * 2011-03-16 2014-12-24 암젠 인크 Nav1.3과 nav1.7의 유효한 선별적 저해제
JP5937197B2 (ja) 2011-04-08 2016-06-22 ユニバーシティー オブ レスター Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN102321170B (zh) * 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
US20140296147A1 (en) 2011-10-06 2014-10-02 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
PT2817329T (pt) * 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polipeptioos que se ligam ao complemento humano c5
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
ES2755104T3 (es) 2012-05-17 2020-04-21 Ra Pharmaceuticals Inc Inhibidores peptídicos y peptidomiméticos
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) * 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
KR20160127042A (ko) 2014-03-20 2016-11-02 인플라알엑스 게엠베하 바이러스성 폐렴의 치료를 위한 c5a의 억제제
NZ727420A (en) * 2014-06-12 2018-06-29 Ra Pharmaceuticals Inc Modulation of complement activity
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
JP2018502870A (ja) 2015-01-21 2018-02-01 パシラ ファーマシューティカルズ インコーポレーテッド トラネキサム酸の多小胞リポソーム処方物
EP3988110A1 (en) 2015-01-28 2022-04-27 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
RS64067B1 (sr) 2015-12-16 2023-04-28 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
US20200282024A1 (en) 2017-09-11 2020-09-10 Ra Pharmaceuticals, Inc. Formulations for compound delivery
BR112020010916A2 (pt) 2017-12-04 2020-11-17 Ra Pharmaceuticals, Inc moduladores da atividade do complemento
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
CN113710230A (zh) 2019-04-24 2021-11-26 Ra制药公司 用于调节补体活性的组合物和方法

Also Published As

Publication number Publication date
RS59353B1 (sr) 2019-10-31
KR102503319B1 (ko) 2023-02-28
US20210246167A1 (en) 2021-08-12
AU2019200828B2 (en) 2021-04-08
RU2018136750A3 (da) 2021-10-19
ZA201900497B (en) 2019-10-30
SI3154561T1 (sl) 2019-11-29
EP3628680B1 (en) 2021-09-08
ES2750556T3 (es) 2020-03-26
BR112016029076A8 (pt) 2022-02-08
RU2016147080A (ru) 2018-06-01
JP2022034057A (ja) 2022-03-02
US11965040B2 (en) 2024-04-23
KR20220002727A (ko) 2022-01-06
CA3241273A1 (en) 2015-12-17
HRP20211561T1 (hr) 2021-12-24
AU2015274482B2 (en) 2018-11-08
CA2949985A1 (en) 2015-12-17
US10106579B2 (en) 2018-10-23
RU2018136750A (ru) 2018-11-06
MX2021009309A (es) 2021-10-26
WO2015191951A2 (en) 2015-12-17
JP6432954B2 (ja) 2018-12-05
CA3174909A1 (en) 2015-12-17
ES2895029T3 (es) 2022-02-17
CY1124595T1 (el) 2022-07-22
IL273746B (en) 2021-03-25
US20200002380A1 (en) 2020-01-02
US10562934B2 (en) 2020-02-18
CN111187338A (zh) 2020-05-22
CY1122227T1 (el) 2020-11-25
DK3154561T3 (da) 2019-10-07
PL3628680T3 (pl) 2022-01-10
IL281264B (en) 2022-05-01
HUE055931T2 (hu) 2022-01-28
BR122021025449B1 (pt) 2024-02-15
KR101981532B1 (ko) 2019-09-02
JP2020128417A (ja) 2020-08-27
AP2016009612A0 (en) 2016-12-31
PT3628680T (pt) 2021-10-07
HUS2400015I1 (hu) 2024-06-28
PT3154561T (pt) 2019-10-25
FIC20240015I1 (fi) 2024-05-28
JP7454545B2 (ja) 2024-03-22
KR20170003993A (ko) 2017-01-10
BR112016029076A2 (pt) 2018-06-05
PL3154561T3 (pl) 2019-12-31
IL273746A (en) 2020-05-31
CN106456701A (zh) 2017-02-22
MX2016016449A (es) 2017-08-24
EP3973994A1 (en) 2022-03-30
JP2019048834A (ja) 2019-03-28
JP2017523232A (ja) 2017-08-17
US10208089B2 (en) 2019-02-19
LT3628680T (lt) 2021-11-25
US20200123202A1 (en) 2020-04-23
NZ727420A (en) 2018-06-29
IL249093A0 (en) 2017-01-31
US20190119328A1 (en) 2019-04-25
BR112016029076B1 (pt) 2024-02-15
CA2949985C (en) 2023-10-17
HUE045646T2 (hu) 2020-01-28
RU2016147080A3 (da) 2018-06-01
KR102346228B1 (ko) 2022-01-04
EP3154561B1 (en) 2019-09-04
EP3154561A4 (en) 2018-04-18
HRP20191763T1 (hr) 2019-12-27
FR24C1022I1 (fr) 2024-07-19
NL301275I2 (nl) 2024-06-20
SG11201610222UA (en) 2017-01-27
WO2015191951A3 (en) 2016-03-03
RS62428B1 (sr) 2021-11-30
AU2021204313A1 (en) 2021-07-22
IL249093B (en) 2020-05-31
US10435438B2 (en) 2019-10-08
BR122023024819A2 (pt) 2023-12-26
EP4223317A2 (en) 2023-08-09
US20180371019A1 (en) 2018-12-27
JP7002597B2 (ja) 2022-02-04
NZ761610A (en) 2024-03-22
HRP20211561T8 (hr) 2022-03-04
KR20190057420A (ko) 2019-05-28
AU2015274482A1 (en) 2017-01-12
JP6770043B2 (ja) 2020-10-14
EP4223317A3 (en) 2023-09-27
IL281264A (en) 2021-04-29
RU2670988C2 (ru) 2018-10-29
US11535650B1 (en) 2022-12-27
SI3628680T1 (sl) 2021-12-31
AU2021204313B2 (en) 2024-01-04
CN111187338B (zh) 2024-08-02
AU2019200828A1 (en) 2019-02-28
LT3154561T (lt) 2019-11-25
ZA202001859B (en) 2021-04-28
US20170137468A1 (en) 2017-05-18
CN106456701B (zh) 2020-01-07
ZA201706379B (en) 2018-12-19
EP3154561A2 (en) 2017-04-19
US11014965B2 (en) 2021-05-25
NZ736573A (en) 2024-03-22
EP3628680A1 (en) 2020-04-01

Similar Documents

Publication Publication Date Title
DK3628680T3 (da) Modulering af komplementaktivitet
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3233887T3 (da) Immunmodulatorer
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3331876T3 (da) Modulators of ror-gamma
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3180331T3 (da) Polymorfer af selinexor
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3389692T3 (da) Modulatorer af komplement-aktivitet
DK3460891T3 (da) Termoelektrokemisk omformer
DK3132009T3 (da) Fremgangsmåde
DK3143123T3 (da) Mikrorna-induktion af kardiologisk regenerering
DK3201323T3 (da) Modificering af bakteriofag
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3511000T3 (da) Krystallinsk form x2 af grapiprant
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3175593T3 (da) Signalering af modulationskonfiguration
DK3418273T3 (da) Derivater af flavagliner
DK3141052T3 (da) Konfiguration af beskyttelsesperiode til LTE HD-FDD
DK3200783T3 (da) Behandling af erytromelalgi
DK3161136T3 (da) Fremgangsmåde til berigelse af mikrovesikler
FR3024647B1 (fr) Transat de puericulture
DK3154942T3 (da) Fremstilling af piperidin-4-carbothioamid
DK2942098T3 (da) Forbedret fremgangsmåde til fjernelse af nitrit
DK3417873T3 (da) Ultrarene hypoallergene opløsninger af sacrosidase